Leading Diabetes Researcher And Educator Dr. Eberhard Standl Joins LabStyle Innovations’ Scientific Advisory Board

CAESAREA, Israel, May 20, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario Diabetes Management Solution, today announced the appointment of Dr. Eberhard Standl to its Scientific Advisory Board. Dr. Standl is an international diabetes expert whose capabilities will assist LabStyle as it seeks to make Dario available for patients around the world.

Dr. Standl has served as President of the German Diabetes Association, German Diabetes Union and International Diabetes Federation Europe as well as Vice President of the International Diabetes Federation and European Association for the Study of Diabetes (EASD). Dr. Standl is a Professor of Medicine, specializing in endocrinology and angiology, at the Munich Diabetes Research Group e.V. at Helmholtz Centre. His principal areas of research include diabetology, action and degradation of insulin and epidemiology of cardiovascular diabetic complications. Previously, Dr. Standl was Director of the Department of Endocrinology, Diabetology and Metabolism at the Academic Hospital Munich-Schwabing. He also worked at the world-renowned Joslin Diabetes Center in Boston, Massachusetts.

“Dr. Standl is a world-renowned diabetes researcher and educator and we are honored to have him join LabStyle’s Scientific Advisory Board,” said Erez Raphael, LabStyle’s President and CEO. “We intend to leverage Dr. Standl’s vast knowledge on the subject of diabetes, and his reputable standing with numerous international diabetes organizations, to help further Dario’s complete diabetes management solution to make life easier for people with diabetes around the globe.”

In addition to the numerous articles, papers and textbook chapters he has published, Dr. Standl has won numerous scientific awards, including the Bertram Award of the German Diabetes Association, the Castelli-Pedroli Prize of the European Association for the Study of Diabetes, the Harold Rifkin Award of the American Diabetes Association and the Hellmut Mehnert Award of the International Diabetes Federation, among others.

“Helping people with diabetes live a free and flexible life, while working to prevent diabetes complications, has been the motivation behind the years of research I have undertaken,” said Dr. Standl. “Dario is a tool that helps accomplish these two objectives and really allows people with diabetes to thrive, not merely manage the disease and I am very excited to begin working with the company.”

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario personalized smart meter. Dario received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario smart meter (Dario Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.com and http://mydario.investorroom.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the performance of the new Scientific Advisory Board appointee as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
© LabStyle Innovations Corp. All rights reserved.

SOURCE LabStyle Innovations Corp.